Variant Bio and Boehringer Ingelheim: Pioneering Cardiovascular Disease Treatments#Seattle#US#Boehringer_Ingelheim#AI_Drug_Discovery#Variant_Bio
Variant Bio and Boehringer Ingelheim: Pioneering Cardiovascular Disease Treatments
Variant Bio expands its partnership with Boehringer Ingelheim to target cardiovascular diseases using AI-driven genomic technology, with a collaboration valued over $250 million.
third-news.com
September 23, 2026 at 12:53 PM
Variant Bio and Boehringer Ingelheim: Pioneering Cardiovascular Disease Treatments#Seattle#US#Boehringer_Ingelheim#AI_Drug_Discovery#Variant_Bio
Variant Bio Strengthens Leadership with Dr. Craig T. Basson as CMO to Enhance Genomic Research#USA#Seattle#Genomics#Variant_Bio#Craig_Basson
Variant Bio Strengthens Leadership with Dr. Craig T. Basson as CMO to Enhance Genomic Research
Variant Bio has appointed Dr. Craig T. Basson as Chief Medical Officer, aiming to leverage his expertise in genomics to advance clinical programs significantly.
third-news.com
January 21, 2026 at 1:21 PM
Variant Bio Strengthens Leadership with Dr. Craig T. Basson as CMO to Enhance Genomic Research#USA#Seattle#Genomics#Variant_Bio#Craig_Basson
Variant Bio Partners with Boehringer Ingelheim to Tackle Kidney Disease Through AI Innovation#USA#Seattle#Boehringer_Ingelheim#kidney_disease#Variant_Bio
Variant Bio Partners with Boehringer Ingelheim to Tackle Kidney Disease Through AI Innovation
Variant Bio has established a significant partnership with Boehringer Ingelheim to facilitate the discovery of new targets for treating kidney disease, utilizing cutting-edge AI technology.
third-news.com
January 6, 2026 at 12:11 PM
Variant Bio Partners with Boehringer Ingelheim to Tackle Kidney Disease Through AI Innovation#USA#Seattle#Boehringer_Ingelheim#kidney_disease#Variant_Bio
Variant Bio Unveils Inference: A Revolutionary AI Genomic Drug Discovery Platform#USA#Seattle#Drug_Discovery#Variant_Bio#AI_Genomics
Variant Bio Unveils Inference: A Revolutionary AI Genomic Drug Discovery Platform
Variant Bio has launched Inference, the groundbreaking AI-powered genomic drug discovery platform, enhancing pharmaceutical research capabilities globally.
third-news.com
January 6, 2026 at 12:05 PM
Variant Bio Unveils Inference: A Revolutionary AI Genomic Drug Discovery Platform#USA#Seattle#Drug_Discovery#Variant_Bio#AI_Genomics
Variant Bio and Novo Nordisk Join Forces for Groundbreaking Metabolic Disease Research#USA#Seattle#Novo_Nordisk#Variant_Bio#metabolic_disease
Variant Bio and Novo Nordisk Join Forces for Groundbreaking Metabolic Disease Research
Variant Bio announces a multi-year partnership with Novo Nordisk to explore novel targets for treating metabolic diseases, enhancing global health opportunities.
third-news.com
January 7, 2025 at 12:14 PM
Variant Bio and Novo Nordisk Join Forces for Groundbreaking Metabolic Disease Research#USA#Seattle#Novo_Nordisk#Variant_Bio#metabolic_disease